Two-thirds of patients admitted to the ICU with an AECOPD are treated with high doses of CS that are associated with worse outcomes and more frequent adverse effects. Lower dosage strategies should be encouraged for patients admitted to the ICU and the optimum dose should be determined through clinical trials.
(Hay que resaltar que el punto de corte de altas/bajas dosis de Corticoides los ponen en 240 mgr/día de metilprednisolona ¡¡¡)
En AJCCRM
No hay comentarios:
Publicar un comentario